27例成人Ph染色体阳性急性淋巴细胞白血病的临床分析被引量：4

Clinical analysis of 27 patients with philadelphia positive acute lymphoblastic leukemia

导出

摘要目的研究伊马替尼及造血干细胞移植治疗Ph+急性淋巴细胞白血病(ALL)的临床疗效。方法收集初诊Ph+ALL患者27例,19例采用伊马替尼联合化疗诱导治疗(IVD组8例,伊马替尼联合VDLP组8例,伊马替尼联合VDP组3例),其余8例给予VDLP常规化疗。22例达完全缓解(CR)后给予伊马替尼联合化疗序贯治疗,3例给予常规维持及巩固化疗,定期监测血常规、骨穿、ABL基因突变及转阴情况。6例行造血干细胞移植,其中1例为自体移植。结果伊马替尼联合化疗诱导治疗CR率可达89.5%,诱导死亡率为0;常规化疗组诱导CR率为50.0%,诱导死亡率为12.5%,两组相比较,差异有统计学意义(P<0.05)。伊马替尼联合化疗诱导治疗组中位缓解持续时间为(10.0±1.4)个月,而常规化疗组仅为2.0个月(P<0.05)。移植患者2年总生存(OS)率75.0%,无病生存期(DFS)为83.3%;未移植患者2年OS率为14.0%,DFS率为12.6%;但两组患者OS率差异无统计学意义(P>0.05),而DFS差异明显(P<0.05)。BCR/ABL转阴患者的OS及DFS均明显高于未转阴患者。结论伊马替尼联合化疗诱导治疗Ph+ALL能提高患者的CR率和缓解持续时间,造血干细胞移植能提高患者的DFS率。 Objective To study the clinical effects of imatinib and hematopoietic stem cell transplantation in Ph＋acute lymphocytic leukemia（ALL）.Methods Collecting 27 new diagnosed patients with Ph＋ ALL in which 19 were assigned to induction treatment with imatinib combined with chemotherapy（8of IVD,8of VDLP and imatinib,3of VDP and imatinib）,the other 8cases were treated with conventional VDLP chemotherapy.22 patients after complete remission（CR）had maintenance therapy combined with imtinib,3patients had maintenance therapy without imtinib.Followed-up the blood routine examination,bone marrow aspiration and ABL fusion gene,6patients had hematopoietic stem cell transplantation（one was auto-HSCT）.Results The CR rate of imatinib combined was higher than the patients without imatinib（89.5%vs.50.0%,P〈0.05）,the induction mortality rate was also higher（0vs.12.5%,P〈0.05）.The median remission duration of imatinib combined and without imatinib were（10.0±1.4）months and 2.0months（P〈0.05）.The disease-free survival（DFS）was significantly longer in patients received allo-HSCT than in those received chemotherapy only（83.3%vs.12.6%,P〈0.05）,but the 2year overall survival（OS）rate was not significantly different（75.0%vs.14.0%,P〉0.05）.Conclusion Imatinib is effective for the induction therapy of Ph＋ ALL.The remission duration of patients who received HSCT is obviously longer than those who received chemotherapy only.

作者杨嫄王利

机构地区重庆医科大学附属第一医院血液内科

出处《重庆医学》 CAS 北大核心 2015年第29期4048-4050,4053,共4页 Chongqing medicine

关键词费城染色体白血病淋巴样急性病伊马替尼造血干细胞移植 philadelphia chromosome leukemia lymphoid acute disease imatinib hematopoietic stem cell transplantation

分类号 R733.71 [医药卫生—肿瘤]

引文网络
相关文献

参考文献12

1Couban S,Savoie L,Mourad YA,et al.Evidence-based guidelines for the use of tyrosine kinase inhibitors in a-dults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia:a Canadian consensus[J].Curr Oncol,2014,21(2):265-309.
2Zhang FH,Ling YW,Zhai X,et al.The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive a-cute lymphoblastic leukemia[J].Hematology?2013,18(3):151-157.
3Lee HJ,Thompson JE,Wang ES,et al.Philadelphia chromosome-positive acute lymphoblastic leukemia:current treatment and future perspectives[J].Cancer,2011,117(8):1583-1594.
4Zhu Y,Qian SX.Clinical efficacy and safety of imatinib in the management of Ph(+)chronic myeloid or acute lymphoblastic leukemia in Chinese patients[J].Onco Targets Ther,2014,7:395-404.
5Hernandez JM,Granada I,Sole F,et al.From conventional cytogenetics to microarrays.Fifty years of Philadelphia chromosome[J].Medicina Clinica,2011,137(5):221-229.
6王建祥.Ph染色体阳性急性淋巴细胞白血病的诊治[J].中华血液学杂志,2014,35(2):98-99. 被引量：5
7Eom KS,Shin SH,Yoon JH,et al.Com-parable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission[J].Am J Hematol,2013,88(8):634-641.
8Lickliter JD,Taylor K,Szer J,et al.An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia:long-term results of the CMLALL1 trial[J].Leuk Lymphoma,2015?56(3):630-638.
9刘霆.Ph阳性急性淋巴细胞白血病的治疗进展与思考[J].中华血液学杂志,2012,33(2):73-75. 被引量：9
10Gruber F,Mustjoki S,Porkka K.Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia[J].Br J Haematol,2009,145(5):581-597.